FTC pulls re­main­ing case against Ab­b­Vie; New EU clin­i­cal tri­als sys­tem com­ing in 2022; Abing­worth bets big on CymaBay

The Fed­er­al Trade Com­mis­sion on Fri­day with­drew its re­main­ing case against Ab­b­Vie af­ter the Supreme Court de­clined to re­view a low­er court’s rul­ing.

The punt by SCO­TUS means that while the Illi­nois phar­ma com­pa­ny il­le­gal­ly blocked pa­tients’ ac­cess to low­er-cost al­ter­na­tives to its testos­terone drug An­dro­Gel, the FTC will no longer be able to re­turn about $500 mil­lion di­rect­ly to An­dro­Gel con­sumers.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER